Soligenix SNGX shares are trading lower after the company said it will not pursue a rolling New Drug Application with the FDA and instead collect more data for a 2022 submission for its HyBryte.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need.
The stock was trading 17.20% lower at $1.06 per share at the time of writing. The stock has a 52-week high $2.99 and a 52-week low of $1.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
